Fidson Healthcare Plc has recorded a profit after tax of N7.7 billion for the first half of 2026, representing a 28 percent increase compared with N6.02 billion reported in the same period of 2025.
The Nigerian pharmaceutical company disclosed the growth in its unaudited half-year financial results, highlighting stronger earnings performance amid continued expansion in the healthcare sector.
The latest figures position Fidson Healthcare as Nigeria’s most capitalised healthcare company, with a market valuation of N273 billion, reflecting investor confidence in the firm’s performance and long-term prospects.
According to Brandspur Banking News Desk, the company’s improved profitability underscores the resilience of Nigeria’s healthcare industry despite operational pressures affecting businesses across the economy.
Fidson Healthcare has continued to strengthen its position in the domestic pharmaceutical market through investments in production capacity, healthcare solutions, and locally manufactured medicines aimed at reducing dependence on imported products.
The company’s financial performance comes amid growing demand for healthcare products in Nigeria, where pharmaceutical firms are increasingly focusing on innovation, supply chain improvements, and local manufacturing to meet rising consumer needs.
The H1 2026 results reinforce Fidson’s role as a major player in Nigeria’s healthcare sector and highlight the increasing importance of domestic pharmaceutical companies in supporting access to essential medicines.
Comments
Start the conversation about this story.